Abstract 450P
Background
Anamorelin (ANAM), a ghrelin receptor agonist, was effective in increasing skeletal muscle mass, weight gain, and appetite in the Ono-7643-05 study for gastrointestinal cancer, including pancreatic cancer (PC) with cancer cachexia (CC), and ANAM was approved in Japan as the world's first treatment for CC. In the Ono-7643-05 study, weight gain and appetite improvement were observed at 3 weeks, and the ANAM package insert states that ANAM should be discontinued if no effectiveness is observed within 3 weeks. The data on factors associated with discontinuation within the first 3 weeks may facilitate the decision to initiate or continue ANAM.
Methods
Patients with unresectable or recurrent PC who started ANAM between 21 April 2021 and 31 March 2022 at the National Cancer Center Hospital and National Cancer Center Hospital East were retrospectively analyzed. Patient characteristics and reasons for discontinuation of ANAM at 3 weeks were collected. Using the clinical data at the time of ANAM initiation, logistic regression analysis was performed to evaluate the background factors associated with the discontinuation of ANAM within 3 weeks.
Results
The study included 110 patients (median age: 70 years; male: 55; Eastern Cooperative Oncology Group performance status 0/1/2/3/unknown: 15/70/15/6/4; prior chemotherapy regimen 0/1/2/3 or more/best supportive care: 5/59/24/15/7 patients). ANAM was discontinued within 3 weeks in 47 patients. The main reasons for discontinuation were disease progression in 23 patients (49%), adverse events (AEs) in 12 patients (26%), and the ineffectiveness of ANAM in 8 patients (17%). The main AEs were gastrointestinal disorders such as nausea and vomiting. Multivariate analysis of factors correlated with the discontinuation of ANAM within 3 weeks revealed a significant association with a Glasgow prognostic score (GPS) of 2.
Conclusions
Among PC patients with CC, the discontinuation rate at 3 weeks after starting ANAM was 43%. The main reason for discontinuation was disease progression. A GPS of 2, which may reflect a high degree of inflammation and low nutritional status, was associated with discontinuation within 3 weeks. Appropriate patient selection may improve the continuation rate of ANAM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center Hospital.
Funding
National Cancer Center Hospital and National Cancer Center Hospital East.
Disclosure
A. Ohba: Financial Interests, Personal, Invited Speaker: Yakult, Ono, Servier, Taiho, Eisai; Financial Interests, Personal, Advisory Board: Zymeworks; Financial Interests, Institutional, Local PI: Ono, Chugai, Novartis. S. Mitsunaga: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical CO., LTD. T. Satake: Financial Interests, Institutional, Local PI: Ono, NIHON Servier. H. Imaoka: Financial Interests, Personal, Invited Speaker: Yakult Honsha, AstraZeneca, Nihon Servier, Kaneka Medix, SB KAWASUMI LABORATORIES; Financial Interests, Personal, Advisory Board: Nihon Servier, Kaneka Medix; Financial Interests, Personal, Writing Engagement: Medico's Hirata; Financial Interests, Institutional, Local PI: Ono Pharmaceutical, Novartis, Nihon Servier. C. Morizane: Financial Interests, Personal, Advisory Board: Yakult, MSD, Servier, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, Merck biopharma; Financial Interests, Personal, Invited Speaker: Novartis, Teijin Pharma; Financial Interests, Institutional, Coordinating PI: Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, Eisai, MSD K.K., J-Pharma, AstraZeneca, Merck biopharma; Financial Interests, Institutional, Funding: Daiichi Sankyo RD Novare, Hitachi. M. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol Myers Squibb, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, Taiho, Yakult, Teijin Pharma, AbbVie, Abbott Japan, Fujifilm Toyama Chemical, Incyte Biosciences Japan, Takeda, Ono, MSD, Taisho Pharmaceutical, Nippon Kayaku, Guardant Health Japan; Financial Interests, Institutional, Coordinating PI: Bayer, Bristol Myers Squibb, Eisai, AstraZeneca, Eli Lilly Japan, Chugai Pharmaceutical, MSD, Ono, Novartis, J-Pharma, Pfizer, Chiome Bioscience, NIHON Servier, Delta-Fly Pharma, Syneos Health, Merus.N.V., Merck biopharma, Boehringer Ingelheim, Invitae; Financial Interests, Personal, Steering Committee Member: Chugai, NIHON Servier, Takeda, Novartis, Eisai, Rakuten Medical. T. Okusaka: Financial Interests, Personal, Advisory Board: Eisai, Nihon Servier, AstraZeneca, Ono Pharmaceutical, FUJIFILM Toyama Chemical, Daiihon-Sumitomo, Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca, Eisai, Chugai Pharma, Nihon Servier, Incyte, Johnson & Johnson, Daiichi Sankyo, Taiho; Financial Interests, Institutional, Local PI: AstraZeneca, Chugai Pharma, Eisai, Novartis, Bristol Myers Squibb, MSD, Incyte, Syneos Health. All other authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract